Neuromuscular Disorders

Featured Article
Patients with Guillain-Barré syndrome with a poor prognosis do not benefit from a second intravenous immunoglobulin dose, according to a study published in The Lancet Neurology.
New best practice guidelines addressing the management and treatment of amyotrophic lateral sclerosis have been published.
The US Food and Drug Administration has approved an oral drug for the treatment of spinal muscular atrophy among patients aged 2 years or older.
There are several types of spinal muscular atrophy that differ in age of onset and muscle weakness severity. Do you know which type is the rarest? Find out by taking our pop quiz.
Are you familiar with which type of spinal muscular atrophy is most common? Find out by taking our pop quiz.
The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of patients aged 5 years and older with Duchenne muscular dystrophy.
There are several types of spinal muscular atrophy, a genetic disorder caused by a loss of motor neurons. Do you know the difference between the types? Find out by taking our Pop Quiz!